SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
STRYKER CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026
$297.94+3.28 (+1.11%)
Close on Oct 19, 2026
- Market cap
- $115.00B
- P/E (TTM)
- 30.9
- Dividend yield
- –
STRYKER CORP revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology: | $3.63B | $3.21B | $4.56B | $3.80B | $3.31B | $3.06B | $3.88B | $3.32B | $3.22B | $3.10B | $3.75B | $2.86B | 55.0% | +9.7% |
| Orthopaedics: | $2.96B | $2.81B | $2.61B | $2.25B | $2.72B | $2.81B | $2.55B | $2.17B | $2.21B | $2.15B | $2.06B | $2.05B | 45.0% | +9.1% |
| Orthopaedics | $2.96B | $2.81B | $2.61B | $2.25B | $2.72B | $2.81B | $2.55B | $2.17B | $2.21B | $2.15B | – | – | 45.0% | +9.1% |
| Operating income | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MedSurg and Neurotechnology: | $1.02B | $700.00M | $1.53B | $1.10B | $846.00M | $757.00M | $1.29B | $966.00M | $903.00M | $847.00M | $1.20B | $859.00M | +20.4% |
| Orthopaedics | $1.01B | $846.00M | $852.00M | $649.00M | $900.00M | $854.00M | $794.00M | $601.00M | $634.00M | $562.00M | – | – | +12.0% |
| Orthopaedics: | – | – | – | – | – | – | – | $643.00M | $676.00M | $605.00M | $698.00M | $499.00M | – |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuro Cranial Instruments | $681.00M | $606.00M | – | – | $616.00M | $563.00M | – | – | – | – | – | – | 10.3% | +10.6% |
| Orthopaedic Instruments | $523.00M | $489.00M | – | – | $501.00M | $484.00M | – | – | – | – | – | – | 7.9% | +4.4% |
| Other Orthopedics | $194.00M | $157.00M | – | – | $148.00M | $133.00M | – | – | – | – | – | – | 2.9% | +31.1% |
| Enabling Technologies | $28.00M | $26.00M | – | – | $34.00M | $29.00M | – | – | – | – | – | – | 0.4% | -17.6% |
| Other MedSurg And Neurotechnology | – | – | – | – | – | – | – | – | – | – | $91.00M | $84.00M | – | – |
| Neuro Cranial - Interventional Spine | – | – | – | – | $129.00M | $118.00M | $117.00M | $100.00M | $98.00M | $98.00M | – | – | – | – |
| Other Orthopedics - Enabling Technologies | – | – | – | – | $34.00M | $29.00M | $58.00M | $32.00M | $31.00M | $31.00M | – | – | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $4.96B | $4.48B | $5.44B | $4.57B | $4.55B | $4.44B | $4.87B | $4.11B | $4.05B | $3.91B | $4.36B | $3.68B | 75.3% | +8.9% |
| International | $1.63B | $1.54B | $1.73B | $1.49B | $1.47B | $1.43B | $1.56B | $1.39B | $1.38B | $1.33B | $1.46B | $1.23B | 24.7% | +11.0% |
From the segment and revenue-disaggregation notes of Stryker's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.